Residency · Residency · Family Medicine

DVT and Pulmonary Embolism: Outpatient Diagnosis and Management

Overview

Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, affects approximately 900,000 Americans annually. Primary care physicians must be proficient in clinical risk stratification, appropriate use of D-dimer testing, imaging selection, and the increasingly common practice of outpatient management with direct oral anticoagulants.

Risk Factors

Risk factors for VTE are classified by whether the event is provoked or unprovoked. Provoked VTE with transient risk factors includes recent surgery, immobilization, hospitalization, long-distance travel, oral contraceptive use, pregnancy or the postpartum period, and trauma. Provoked VTE with persistent risk factors involves active malignancy or autoimmune disease. Unprovoked VTE occurs without any identifiable risk factor and carries a higher risk of recurrence. Inherited thrombophilias include Factor V Leiden mutation, prothrombin G20210A mutation, protein C and S deficiency, antithrombin deficiency, and antiphospholipid syndrome. Additional risk factors include obesity, advancing age, smoking, varicose veins, prior VTE, and the presence of a central venous catheter.

DVT Evaluation

Clinical Presentation

DVT typically presents with unilateral leg swelling, pain, warmth, and erythema. Calf tenderness and pitting edema may be present. Homan sign, while historically taught, is unreliable because of poor sensitivity and specificity. The differential diagnosis includes cellulitis, ruptured Baker cyst, superficial thrombophlebitis, lymphedema, muscle strain, and chronic venous insufficiency.

Wells Score for DVT

The Wells score for DVT assigns points for active cancer, paralysis or immobilization of a lower extremity, being bedridden for more than 3 days or having had surgery within 12 weeks, localized tenderness along the deep venous system, entire leg swelling, calf swelling greater than 3 cm compared to the asymptomatic leg, pitting edema, collateral superficial veins, and previously documented DVT, each earning one point. An alternative diagnosis being as likely or more likely than DVT subtracts two points. A score of 1 or below classifies DVT as unlikely, prompting D-dimer testing. A score of 2 or above classifies DVT as likely, warranting direct proceeding to ultrasound.

Diagnostic Pathway

When DVT is unlikely based on a Wells score of 1 or below, a high-sensitivity D-dimer should be obtained. If negative, DVT is effectively excluded, with a negative predictive value exceeding 99%. If the D-dimer is positive, compression ultrasound is the next step. When DVT is likely based on a Wells score of 2 or above, compression ultrasound should be performed directly. If the ultrasound is positive, treatment is initiated. If negative but clinical suspicion remains high, repeat ultrasound in 5 to 7 days or D-dimer testing should be pursued.

Age-Adjusted D-Dimer

The standard D-dimer threshold is 500 ng/mL. For patients over age 50, an age-adjusted threshold calculated as the patient's age multiplied by 10 ng/mL (for example, 650 ng/mL for a 65-year-old) increases specificity in elderly patients without reducing sensitivity. This approach has been validated in multiple studies and reduces unnecessary imaging by 10 to 15%.

Imaging

Compression ultrasonography is the first-line imaging modality, with sensitivity exceeding 95% for proximal DVT. Proximal DVT involving the popliteal vein and above carries a higher risk of pulmonary embolism and always requires treatment. Isolated distal DVT below the knee carries lower PE risk, and management options include anticoagulation or serial ultrasound monitoring at 1 and 2 weeks.

Pulmonary Embolism Evaluation

Clinical Presentation

Dyspnea is the most common symptom of PE, followed by pleuritic chest pain, cough, and rarely hemoptysis. Physical findings may include tachycardia, tachypnea, and hypoxia, though oxygen saturation can be normal. Syncope suggests massive PE with hemodynamic compromise. Signs of DVT are present in fewer than 50% of PE cases.

Wells Score for PE

The Wells score for PE assigns points for clinical signs and symptoms of DVT (3 points), PE as likely or more likely than an alternative diagnosis (3 points), heart rate above 100 (1.5 points), immobilization or surgery in the prior 4 weeks (1.5 points), previous VTE (1.5 points), hemoptysis (1 point), and malignancy (1 point). A score of 4 or below classifies PE as unlikely, prompting D-dimer testing first. A score above 4 classifies PE as likely, warranting direct CT pulmonary angiography.

PERC Rule (Pulmonary Embolism Rule-Out Criteria)

The PERC rule is applied only when pre-test probability is low, below 15%. All eight criteria must be met to rule out PE without further testing: age below 50, heart rate below 100, oxygen saturation of 95% or above, no hemoptysis, no estrogen use, no prior DVT or PE, no unilateral leg swelling, and no surgery or hospitalization within 4 weeks. When all PERC criteria are met, no D-dimer is needed and PE can be excluded clinically.

Diagnostic Pathway

When PE is unlikely based on a Wells score of 4 or below, the PERC rule is applied first. If the patient fails PERC, a D-dimer is obtained. A negative D-dimer excludes PE, while a positive result prompts CT pulmonary angiography. When PE is likely based on a Wells score above 4, CTPA should be performed directly. CTPA is the imaging modality of choice, with sensitivity and specificity both exceeding 95%. A V/Q scan is an alternative for patients with contrast allergy, renal insufficiency, or pregnancy, as it delivers a lower radiation dose to breast tissue.

Subsegmental PE

Isolated subsegmental PE remains a topic of clinical debate. It may represent a false positive or a clinically insignificant finding. If no proximal DVT is found on leg ultrasound and clinical risk is low, observation without anticoagulation may be reasonable. Shared decision-making is appropriate, and guidelines increasingly support selective treatment.

Treatment

DOAC-Based Anticoagulation (First-Line)

Direct oral anticoagulants are first-line therapy for VTE. Rivaroxaban follows a single-drug approach: 15 mg twice daily for 21 days, then 20 mg daily, with no lead-in parenteral anticoagulation needed. Apixaban also uses a single-drug approach: 10 mg twice daily for 7 days, then 5 mg twice daily. Edoxaban at 60 mg daily requires 5 to 7 days of lead-in parenteral anticoagulation with LMWH. Dabigatran at 150 mg twice daily similarly requires 5 to 7 days of lead-in parenteral anticoagulation.

LMWH

Enoxaparin dosed at 1 mg/kg subcutaneously twice daily or 1.5 mg/kg subcutaneously once daily is used as lead-in therapy for edoxaban and dabigatran, as a bridge for cancer-associated VTE, and during pregnancy. It is preferred over unfractionated heparin for most patients because of its predictable pharmacokinetics and the absence of routine monitoring requirements in most cases.

Warfarin

Warfarin has been largely supplanted by DOACs for VTE treatment but remains appropriate in certain situations: antiphospholipid syndrome (where DOACs are inferior), severe renal impairment, patient preference, and cost constraints. The target INR is 2.0 to 3.0, and LMWH bridging is required for at least 5 days and until the INR has been 2.0 or above for 24 hours.

Duration of Anticoagulation

VTE provoked by a transient risk factor such as surgery or immobilization requires 3 months of anticoagulation. A first unprovoked VTE warrants a minimum of 3 months followed by reassessment of the risk-benefit balance for extended therapy. Recurrent unprovoked VTE generally requires indefinite anticoagulation unless bleeding risk is prohibitive. Cancer-associated VTE should be treated with LMWH or a DOAC (edoxaban or rivaroxaban) for the duration of active cancer, with a minimum of 6 months.

Extended Anticoagulation Assessment

Several factors inform the decision to extend anticoagulation. An elevated D-dimer after completing 3 months of therapy suggests higher recurrence risk and favors extended treatment. Male sex carries a higher recurrence risk than female sex. Proximal DVT and PE carry higher recurrence risk than distal DVT. Residual DVT on ultrasound may indicate higher recurrence risk. Bleeding risk should be assessed using tools such as HAS-BLED or VTE-BLEED scores. Reduced-dose options for extended therapy include apixaban at 2.5 mg twice daily and rivaroxaban at 10 mg daily, which the AMPLIFY-EXT and EINSTEIN-CHOICE trials demonstrated maintain efficacy with lower bleeding risk.

Outpatient Management of PE

Criteria for Outpatient Treatment (Hestia Criteria / sPESI)

Outpatient management of PE is appropriate for hemodynamically stable patients with systolic blood pressure of 90 mmHg or above who do not require supplemental oxygen, IV analgesia, or thrombolysis, have no active bleeding or high bleeding risk, no severe renal or hepatic disease, are not pregnant, and have a reliable social situation with follow-up capability. An sPESI score of 0 identifies low-risk PE with an approximately 1% 30-day mortality.

Practical Outpatient Protocol

A DOAC is started in the emergency department or office after confirming the diagnosis. Close follow-up occurs within 48 to 72 hours by phone or in person, with subsequent visits at 1 week, 1 month, and 3 months. Patients receive education on when to seek emergency care for worsening dyspnea, chest pain, hemoptysis, or signs of bleeding.

Massive and Submassive PE

Massive PE

Massive PE is defined by hemodynamic instability with sustained systolic blood pressure below 90 mmHg for more than 15 minutes. Treatment involves systemic thrombolysis with alteplase 100 mg IV over 2 hours or catheter-directed therapy. Surgical embolectomy is reserved for cases where thrombolysis is contraindicated.

Submassive PE

Submassive PE describes hemodynamically stable patients with evidence of right ventricular strain, including RV dilation on CT or echocardiography, elevated troponin, or elevated BNP. These patients require close monitoring in an ICU or step-down unit with anticoagulation. Thrombolysis is not routinely recommended based on the PEITHO trial, which showed reduced hemodynamic decompensation but increased major bleeding. It may be considered if clinical deterioration occurs.

Thrombophilia Testing

Thrombophilia testing should not be performed in the acute setting because results are unreliable during active VTE and while on anticoagulation. It is not recommended after provoked VTE with a transient risk factor, as the results do not change management. Testing may be considered after unprovoked VTE in young patients under 50 if results would influence the duration of anticoagulation. Antiphospholipid syndrome is the most clinically significant thrombophilia and should be tested for in unprovoked VTE, recurrent VTE, or VTE at unusual sites. Testing should occur at least 2 weeks after stopping anticoagulation, as DOACs interfere with some thrombophilia assays.

<image>A clinical decision algorithm showing the DVT and PE diagnostic pathways in parallel. For DVT: Wells score leading to D-dimer or ultrasound. For PE: Wells score with PERC rule leading to D-dimer or CTPA. Show decision nodes, test results, and final dispositions (treat, exclude, or further workup). Include age-adjusted D-dimer thresholds.</image>

<image>An anticoagulation treatment guide for VTE showing the four DOAC regimens (rivaroxaban, apixaban, edoxaban, dabigatran) with their lead-in requirements, dosing phases, and extended therapy options. Include a visual timeline showing the initial treatment phase (first 7-21 days), main treatment phase (3-6 months), and extended treatment phase with reduced-dose options.</image>

<image>A risk stratification framework for PE showing the spectrum from low-risk (outpatient management with sPESI = 0) through submassive (RV strain, elevated biomarkers) to massive PE (hemodynamic instability), with the recommended treatment approach at each severity level including anticoagulation alone, close monitoring, and thrombolysis/catheter-directed therapy.</image>

Clinical Pearls

The PERC rule can safely exclude PE without any testing in low pre-test probability patients, and it should be used to reduce unnecessary D-dimer orders. Age-adjusted D-dimer cutoffs reduce false positives and unnecessary imaging in elderly patients without sacrificing safety. DOACs are first-line for VTE treatment, and rivaroxaban and apixaban offer single-drug approaches without the need for lead-in parenteral anticoagulation. Low-risk PE can be safely managed in the outpatient setting, with the sPESI score and Hestia criteria guiding this decision. Duration of anticoagulation is the most important decision in VTE management, and unprovoked VTE often warrants extended therapy with periodic reassessment. Subsegmental PE in the absence of proximal DVT may not require anticoagulation, though this is an evolving area requiring shared decision-making. Thrombophilia testing should not be performed during acute VTE or while on anticoagulation because results are unreliable and rarely change management. Cancer-associated VTE requires longer treatment and carries higher recurrence risk; DOACs are increasingly accepted, but LMWH remains preferred for gastrointestinal and genitourinary malignancies because of higher bleeding risk with DOACs.

References

• Kearon C et al. CHEST Guideline: Antithrombotic Therapy for VTE Disease. Chest. 2021
• Konstantinides SV et al. 2019 ESC Guidelines for Acute Pulmonary Embolism. Eur Heart J. 2020
• Agnelli G et al. Apixaban for Extended Treatment of VTE (AMPLIFY-EXT). NEJM. 2013
• Weitz JI et al. Rivaroxaban for Extended VTE Treatment (EINSTEIN-CHOICE). NEJM. 2017
• Meyer G et al. PEITHO: Thrombolysis for Submassive PE. NEJM. 2014
• Righini M et al. Age-Adjusted D-Dimer for PE Diagnosis (ADJUST-PE). JAMA. 2014
• Kline JA et al. PERC Rule Validation. J Thromb Haemost. 2008

Read this lecture as Markdown